Rapamycin

eRapa™ inhibits the progression and recurrence of cancer. Research has shown eRapa rejuvenates the immune system exhausted by age and cancer exposure. Click here to read more.

eRapa™ was developed at the Barshop Institute for Longevity and Aging Studies at the University of Texas Health Science Center at San Antonio, and is the only pharmaceutical agent tested thus far to demonstrate significantly increased health span and lifespan in rodent models. Click here to read more.

Early evidence shows a potential for eRapa™ to prevent the progression of prostate cancer and Familial Adenomatous Polyposis, a precursor to colon cancer, meeting a significant unmet need in the marketplace. Click here to read more.

Scientists at the Barshop Institute have demonstrated that orally administered eRapa™ can prevent the development of Alzheimer’s pathologies in mice. Click here to read more.

Over the past decade, Rapamycin has shown promise as a drug that not only can extend life by delaying the onset of aging-related diseases such as cancer, heart disease, and Alzheimer’s disease, but also postpone the effects of normal aging. Click here to read more.